Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ad5 nCOV - Tianjin CanSino Biotechnology

Next Previous
Drug Profile

Ad5 nCOV - Tianjin CanSino Biotechnology

Alternative Names: 5E10 vp; Ad5-nCOV - Tianjin CanSino Biotechnology; Ad5-nCoV-IH; Adenovirus type-5 vectored COVID-19 vaccine; Convidecia; COVID-19 vaccine - Tianjin CanSino Biotechnology; Low dose adenovirus type-5 vectored COVID-19 vaccine; Recombinant Coronavirus Vaccine - Tianjin CanSino Biotechnology; Recombinant novel coronavirus vaccine (adenovirus type 5 vector) - Tianjin CanSino Biotechnology; Recomboinant novel coronavirus vaccine - Tianjin CanSino Biotechnology

Latest Information Update: 28 Oct 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Tianjin CanSino Biotechnology
  • Developer Beijing Institute of Biotechnology; Tianjin CanSino Biotechnology
  • Class COVID-19 vaccines; Synthetic vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Registered COVID 2019 infections

Most Recent Events

  • 28 Oct 2023 No recent reports of development identified for phase-I development in COVID-2019-infections(Prevention) in China (Transmucosal, Injection)
  • 18 Jun 2023 CanSino Biologics in collaboration with Beijing Institute of Biotechnology withdraws a planned phase III SeiHOPE trial for COVID-2019 infections (Prevention) in China (Inhalation) (NCT05124561)
  • 10 Feb 2023 Tianjin CanSino Biotechnology completes a phase III trial in COVID-2019-infections in China (NCT04916886)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top